Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 1, 2025
Finance
Metsera, Maze land on NASDAQ as IPO queue grows
BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
BioCentury | Aug 23, 2024
Emerging Company Profile
Borealis: Versant, Novartis launch Chinook’s RNA-targeting sequel
The research team behind Chinook are taking on renal diseases with cell type-specific delivery of oligonucleotide therapies.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | May 1, 2023
Deals
Maze-Sanofi deal in Pompe shows how early clinical data can drive pharma deals
Pharma extends rare disease franchise, paying well-funded biotech $150M in cash and equity investment to embrace substrate reduction approach
BioCentury | Feb 9, 2023
Product Development
Catalysts beyond cystic fibrosis await Vertex after $8.9B year
Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease
BioCentury | Mar 31, 2022
Product Development
Amid push to diversify beyond CF, Vertex’s pain readout sets up pivotal program
After latest win for a homegrown product, Vertex’s sodium channel blocker poised to enter pivotal study by year-end
BioCentury | Dec 8, 2021
Deals
Eyeing pair of amyloidosis indications, AZ in deal for Ionis asset
AZ pays $200M up front for ‘immediate’ opportunity in one indication, larger population in another
BioCentury | Jun 11, 2021
Product Development
After suboptimal Phase II readout, Vertex looks to learn from experience as it optimizes next-generation AAT products
It may take Vertex longer to optimize its AAT therapy than it expected, but this time, the biotech can apply lessons learned from its similar experience developing cystic fibrosis therapies. Although
Items per page:
1 - 10 of 11